The Frederick National Lab has begun to assist several major pharmaceutical companies in adopting nanotechnologies in early stage drug development, when the approach is most efficient and cost-effective.
Sen. Barbara Mikulski came to NIH on April 11 to say goodbye.
Following this fall’s election, the longest-serving woman in congressional history will relinquish her Maryland Senate seat, bringing to a close a 40-year national political career in which she staunchly supported NIH and biomedical research.
NCI recently announced the launch of the new National Cryo-Electron Microscopy Facility (NCEF) at the Frederick National Laboratory for Cancer Research (FNLCR). The launch comes while cryo-electron microscopy (cryo-EM) is enjoying the spotlight as a newly emerging, rapidly evolving technology with the potential to revolutionize the field of structural biology. Read more...
In October 2015, the NCI executive officer and the director of NCI’s Office of Space and Facilities Management (OSFM) announced a wide-ranging refurbishment plan for NCI at Frederick. Since then, a project team comprising members from the Office of Scientific Operations, the Management Operations Support Branch, OSFM, the Center for Cancer Research, the Environment, Health, and Safety (EHS) directorate, and the Facilities Maintenance and Engineering (FME) directorate have met regularly with the laboratory groups affected by the refurbishment plan. Read more...
A monoclonal antibody has proven effective in preventing Middle Eastern Respiratory Syndrome (MERS) in lab animals, suggesting further development as a potential intervention for the deadly disease in humans, according to new research.
MERS is a newly emerged coronavirus first detected in humans in 2012. Most cases have occurred in the Middle East, but the disease has appeared elsewhere. In all, MERS has infected more than 1,700 individuals and killed more than 600, according to the World Health Organization. No vaccines or antiviral therapies currently exist. Several candidate vaccines are being developed, and some have been tested in animal models, a prerequisite to human clinical trials.
Many aspects of how infectious viruses assemble in cells have yet to be completely deciphered. However, as reported in a recent Journal of Virology paper, researchers may be one step closer to understanding how HIV-1, the virus that causes AIDS, assembles and replicates.
NCI at Frederick employees have a unique opportunity to contribute directly to cancer and AIDS research by donating blood, saliva, and other samples through the Research Donor Program (RDP). Donors are compensated for their time, which is typically between 10 and 30 minutes.
The RDP, which is administered by Occupational Health Services (OHS), Leidos Biomedical Research, provides samples from healthy donors for use in in vitro research conducted at NCI at Frederick and Fort Detrick. Samples are provided anonymously to researchers.
Scientists throughout NCI gathered at the 2016 Intramural Scientific Investigators Retreat on Jan. 12, at the Ronald Reagan Building and International Trade Center, to discuss the results of their research with fellow investigators.
Several researchers who have made significant advances toward the goal of eliminating the threat of cancer spoke to a packed auditorium of like-minded experts. Speaker topics included the role genetics play in the risk of breast cancer, using fiberglass to...
An herbal extract used for centuries to prevent heart disease has now been shown to be effective against colorectal cancer when tested in laboratory cell cultures.
Scientists from NCI at Frederick found that the natural extract cryptotanshinone (CPT) stops the uncontrolled cell growth characteristic of cancer by interfering with a protein that has been implicated in several cancers, including those of the colon and rectum. The results appear in the journal Molecular and Cellular Biochemistry.
Eric Betzig, Ph.D., a 2014 recipient of the Nobel Prize in Chemistry and a scientist at Janelia Research Campus (JRC), Howard Hughes Medical Institute, in Ashburn, Va., visited NCI at Frederick on Sept. 10 to present a Distinguished Scientist lecture and discuss the latest high-resolution microscopy techniques.
Betzig co-invented photoactivation localization microscopy (PALM) in collaboration with scientists at NIH. PALM achieves 10-fold improvement in spatial resolution of cells, going from the resolution limit of approximately 250 nm in standard optical microscopy down to approximately 20 nm, thus producing a so-called “super-resolution” image. Spatial resolution refers to the clarity of an image or, in other words, the smallest details that can be observed from an image.
